Techsonian (press release) The company's lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the cure of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in ... and more »
Seeking Alpha (registration) Ciprofoxacin is a second-generation quinolone first patented by Bayer (OTCQX: OTCPK:BAYRY) in 1987 that is broadly used to treat Gram-negative and Gram-positive bacteria, although not methicillin-resistant Staphylococcus aureus "MRSA". Two Phase 3 ...
Medical News Today They then used the system to target another gene called SHV-18, a mutation in the bacterial chromosome that makes them resistant to quinolone antibi...
